Lundbeck to Cut 600 Sales Jobs in Europe on Drug Lineup

H. Lundbeck A/S (LUN), the Nordic region’s second-largest drugmaker, said it’s eliminating 600 sales jobs in Europe as it prepares new products that will lead to a change in its lineup.

Reorganization costs may total as much as 500 million kroner ($85 million) this year, the Copenhagen-based company said in a statement today. The job cuts will affect sales personnel who work with general practitioners, said Mads Kronborg, a spokesman.

Lundbeck expects European approval of its alcoholism treatment nalmefene by the end of 2012. It’s also planning to submit a new antidepressant, known as LU AA21004, for regulatory clearance in the U.S. and Europe later this year.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.